Evaluation of new subjects continues at the trial’s active centers in Adelaide, Brisbane and Sydney, Australia, as well as at MD Anderson, St Luke’s and the California Pacific Medical Center in the US. The 40th subject was treated at the Royal Adelaide Hospital in Australia.
A further update on the study status is planned in mid-March of 2009 in New York City. Safety data from the first 40 subjects, and interim efficacy data from the first 20 subjects is expected to be reported during the same period.
Craig Dees, CEO of Provectus, said: “Enrollment of the 40th subject represents another significant milestone for Provectus Pharmaceuticals. With 50% of the subjects in the Phase II melanoma clinical trial already treated, we can continue to gather the data necessary to explore regulatory approval. With the recent addition of several more centers to the study we expect enrollment of the second half of subjects to continue at an accelerated pace.”